Stifel Financial Corp Has $530,000 Position in Codexis, Inc. (NASDAQ:CDXS)

Stifel Financial Corp decreased its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 38.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 172,186 shares of the biotechnology company's stock after selling 106,466 shares during the period. Stifel Financial Corp owned approximately 0.21% of Codexis worth $530,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of CDXS. Los Angeles Capital Management LLC acquired a new stake in Codexis during the second quarter worth approximately $54,000. Intech Investment Management LLC acquired a new stake in shares of Codexis during the 3rd quarter worth $66,000. Marshall Wace LLP acquired a new stake in shares of Codexis during the 2nd quarter worth $89,000. Algert Global LLC increased its position in shares of Codexis by 17.1% in the second quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company's stock worth $129,000 after purchasing an additional 6,069 shares during the period. Finally, Squarepoint Ops LLC lifted its position in Codexis by 113.8% during the second quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company's stock worth $231,000 after purchasing an additional 39,664 shares during the period. Institutional investors and hedge funds own 78.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Benchmark reissued a "hold" rating on shares of Codexis in a report on Monday, November 4th. Cantor Fitzgerald reiterated an "overweight" rating and set a $11.00 price target on shares of Codexis in a research report on Friday, November 22nd.

Codexis Price Performance

NASDAQ:CDXS traded up $0.02 during trading hours on Friday, hitting $4.99. The company's stock had a trading volume of 612,044 shares, compared to its average volume of 567,803. Codexis, Inc. has a twelve month low of $2.53 and a twelve month high of $6.08. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The stock has a fifty day simple moving average of $4.38 and a 200-day simple moving average of $3.54. The company has a market capitalization of $406.08 million, a P/E ratio of -5.74 and a beta of 2.15.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). The company had revenue of $12.83 million during the quarter, compared to analyst estimates of $11.64 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. During the same quarter in the previous year, the business posted ($0.26) earnings per share. On average, analysts anticipate that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.